Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Tables)

Discontinued Operations (Tables)

3 Months Ended

Nov. 30, 2021

Discontinued Operations

Schedule of gain on assest disposal

Gain on asset disposal
Book value of assets sold		$	-
Cash consideration			273,373
Shares received			468,264
Shares receivable			781,067
Promissory note			-
		$	1,522,704

Schedule of income loss of discontinued operation

		THREE MONTHS ENDED
		November 30,
		2021				2020
Revenue		$	-			$	3,000
Operating Expenses			-				-
Net Income (loss)		$	-			$	3,000

		THREE MONTHS ENDED
		November 30,
		2021				2020
Cash flows used in discontinued operating activities
Net income		$	-			$	3,000
Change in working capital			-				55,667
Net cash used in discontinued operating activities		$	-			$	58,667

Net cash provided by discontinued operations			-			$	58,667

Schedule of assest sold

		November 30,				August 31,
		2021				2020
Current Assets
Accounts receivable		$	-			$	49,333
Total assets classified as discontinued operations in the consolidated balance sheet			-				49,333

Current Liabilities
Accounts payable			-				-
Total liabilities classified as discontinued operations in the consolidated balance sheet		$	-			$	-